User login
Key clinical point: Obesity increased the risk for recurrence in postmenopausal women with early-stage hormone receptor-positive (HR+) breast cancer (BC) who were treated with aromatase inhibitors (AI).
Major finding: Among patients with AI-treated HR+ BC, the risk for BC recurrence was significantly higher in those with obesity (adjusted hazard ratio [aHR] 1.18; 95% CI 1.01-1.37) and severe obesity (aHR 1.32; 95% CI 1.08-1.62) than in those with a healthy weight.
Study details: Findings are from a nationwide cohort study including 13,230 postmenopausal women with stages I-III HR+ BC who received AI.
Disclosures: This study was supported by the Jeppe Juhl Memorial Foundation, Denmark, and other Danish sources. Jensen MR declared receiving from Novartis meeting expenses and personal fees unrelated to this study.
Source: Harborg S et al. Obesity and risk of recurrence in patients with breast cancer treated with aromatase inhibitors. JAMA Netw Open. 2023;6(10):e2337780 (Oct 13). doi: 10.1001/jamanetworkopen.2023.37780
Key clinical point: Obesity increased the risk for recurrence in postmenopausal women with early-stage hormone receptor-positive (HR+) breast cancer (BC) who were treated with aromatase inhibitors (AI).
Major finding: Among patients with AI-treated HR+ BC, the risk for BC recurrence was significantly higher in those with obesity (adjusted hazard ratio [aHR] 1.18; 95% CI 1.01-1.37) and severe obesity (aHR 1.32; 95% CI 1.08-1.62) than in those with a healthy weight.
Study details: Findings are from a nationwide cohort study including 13,230 postmenopausal women with stages I-III HR+ BC who received AI.
Disclosures: This study was supported by the Jeppe Juhl Memorial Foundation, Denmark, and other Danish sources. Jensen MR declared receiving from Novartis meeting expenses and personal fees unrelated to this study.
Source: Harborg S et al. Obesity and risk of recurrence in patients with breast cancer treated with aromatase inhibitors. JAMA Netw Open. 2023;6(10):e2337780 (Oct 13). doi: 10.1001/jamanetworkopen.2023.37780
Key clinical point: Obesity increased the risk for recurrence in postmenopausal women with early-stage hormone receptor-positive (HR+) breast cancer (BC) who were treated with aromatase inhibitors (AI).
Major finding: Among patients with AI-treated HR+ BC, the risk for BC recurrence was significantly higher in those with obesity (adjusted hazard ratio [aHR] 1.18; 95% CI 1.01-1.37) and severe obesity (aHR 1.32; 95% CI 1.08-1.62) than in those with a healthy weight.
Study details: Findings are from a nationwide cohort study including 13,230 postmenopausal women with stages I-III HR+ BC who received AI.
Disclosures: This study was supported by the Jeppe Juhl Memorial Foundation, Denmark, and other Danish sources. Jensen MR declared receiving from Novartis meeting expenses and personal fees unrelated to this study.
Source: Harborg S et al. Obesity and risk of recurrence in patients with breast cancer treated with aromatase inhibitors. JAMA Netw Open. 2023;6(10):e2337780 (Oct 13). doi: 10.1001/jamanetworkopen.2023.37780